Fill in the form below and our experts will get back to you within 1 business day.
Accelerate your functional genomics research with genome-wide CRISPR/Cas9 knockout libraries. Our comprehensive platform delivers high-quality sgRNA libraries with validated efficiency for robust genetic screening in drug discovery and target validation.
Trusted by leading research and pharmaceutical institutions
Our CRISPR/Cas9 knockout libraries enable genome-wide loss-of-function screening with validated efficiency and comprehensive coverage for drug discovery and functional genomics research.
High-titer lentiviral pooled libraries enable efficient transduction into a wide range of cell types including difficult-to-transfect and primary cells. Each library undergoes rigorous quality control with NGS verification to ensure uniform representation.
Arrayed formats enable high-content phenotypic screening without the need for NGS deconvolution. Ready-to-transfect synthetic guides simplify workflows and accelerate discovery timelines.
Computationally optimized sgRNAs with proven on-target activity and minimized off-target effects using established design algorithms.
Every library undergoes next-generation sequencing verification with detailed QC reports for complete transparency.
Flexible options for genome-wide, pathway-focused, or user-defined gene sets to match your research objectives.
Get a customized quote for your CRISPR knockout library screening project.
State-of-the-art platforms delivering high-efficiency knockout with validated performance.
Optimized sgRNA designs using established algorithms including Rule Set 2/3 for enhanced on-target activity. Multiple guides per gene ensure robust knockout efficiency.
Advanced lentiviral packaging systems achieve high-titer preparations (≥10^8 TU/mL) for efficient transduction across diverse cell types including primary cells.
Comprehensive quality control with NGS verification ensures library uniformity, coverage, and representation across all preparations.
Our libraries employ a multi-guide design strategy with 4-6 sgRNAs per gene to ensure robust and consistent knockout efficiency. This approach addresses variability in sgRNA performance and provides redundant coverage for confident hit identification.
Comprehensive specifications for our CRISPR knockout library products.
| Species | Gene Coverage | sgRNA Count | Format |
|---|---|---|---|
| Human | 20,000+ | 76,000-123,000 | Plasmid / Virus / Arrayed |
| Mouse | 20,000+ | 86,000+ | Plasmid / Virus / Arrayed |
| Rat | Available | Custom | Plasmid / Virus |
| Custom Species | On request | Custom | Custom |
A streamlined end-to-end process from library delivery to hit identification.
Receive high-titer lentiviral library with NGS QC report. Amplify library if needed following our validated protocol.
Transduce Cas9-expressing cells at low MOI (0.3-0.6) to ensure single sgRNA per cell. Maintain 200-500x coverage.
Apply phenotypic selection (drug treatment, FACS, survival) based on your experimental design.
Extract genomic DNA, amplify sgRNA regions, and perform Illumina NGS for sgRNA abundance quantification.
Bioinformatic analysis using MAGeCK or similar tools to identify enriched/depleted genes from screen data.
Our CRISPR knockout libraries support research and development across multiple fields.
Identify and validate therapeutic targets through genome-wide loss-of-function screening. Our libraries enable systematic interrogation of genetic dependencies for novel drug target discovery.
Discover cancer vulnerabilities and resistance mechanisms through systematic genetic screening. Identify essential genes and synthetic lethal interactions for therapeutic development.
Systematically characterize gene function across the genome. Our libraries enable comprehensive functional annotation for understanding biological pathways and cellular mechanisms.
Trusted by researchers worldwide for quality and reliability.
"The library quality exceeded our expectations. Consistent coverage and uniform distribution across all samples. NGS verification reports were comprehensive and helped us validate our screening results."
"The multi-guide design significantly improved our hit detection rate. Customer support was responsive and provided valuable technical guidance throughout our screening project."
"Successfully identified novel drug targets in our oncology screening. The library coverage and delivery format made the entire workflow straightforward and efficient."
Our platform is backed by peer-reviewed research.
Chan YT, Lu Y, Wu J, Zhang C, et al. Theranostics. 2022;12(7):3329-3344.
Comprehensive review of CRISPR-Cas9 pooled library screening technology for anti-cancer drug discovery, covering positive and negative selection methods, experimental models, and target identification applications.
Mathiowetz AJ, Roberts MA, Morgens DW, Olzmann JA, Li Z. STAR Protocols. 2023;4(2):102201.
Detailed protocol for designing, amplifying, and screening pooled CRISPR-Cas9 knockout libraries in mammalian cells, including phenotypic selection and NGS analysis.
Ngan DK, et al. Current Protocols. 2023.
Framework for performing pooled CRISPR-Cas9 tiling mutagenesis screens with drug selection to identify drug resistance mutations, including sgRNA library design and analysis.
Multiple authors. Experimental & Molecular Medicine. 2025;57:1443-1454.
Review of CRISPR-based perturbomics advances including single-cell analyses, synthetic lethality interactions, and therapeutic target discovery for cancer and other diseases.
Multiple authors. Stem Cell Research & Therapy. 2024.
Comprehensive review of CRISPR-based functional genomics screening applications in stem cells, covering library design, screening protocols, and therapeutic applications.
Find answers to common questions about our CRISPR knockout library services.
Get a customized quote for your CRISPR/Cas9 Knockout Libraries project. Our experts will respond within 24 hours.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.